reviewThe Journal of Prevention of Alzheimer s DiseaseFeb 25, 2025DIAMOND OA

Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics

Centre National de la Recherche Scientifique · Inserm · +22 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European Medicines Agency. An Early Market Authorization could be submitted to the French regulatory agencies, potentially allowing for the drug's use in clinical practice in France in 2025. To guide French clinicians in administering lecanemab in a standardized way, the French Federation of Memory Clinics has developed appropriate use recommendations for lecanemab that highlight relevant questions established to ensure an optimal risk-benefit ratio. The recommendations emphasize that lecanemab…

No related works found for this paper.